BLOCK-SAH is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical
trial with a sequential parallel comparison design (SPCD) of bilateral pterygopalatine fossa
(PPF) injections with 20mg ropivacaine + 4mg dexamethasone (active, PPF-block) compared to
saline (placebo) for headache in survivors of aneurysmal subarachnoid hemorrhage (SAH), while
monitoring intracranial arterial mean flow velocities with transcranial Doppler (TCD)
peri-intervention (intervention = PPF-injections: active or placebo)
Phase:
Phase 2
Details
Lead Sponsor:
University of Florida
Collaborators:
Massachusetts General Hospital National Institute of Neurological Disorders and Stroke (NINDS) New York University